440 publications from this institution
Heme oxygenase-1 (HO-1) is an enzyme contributing to the development and progression of different cancer types. HO-1 plays a role in pathological angiogenesis in bladder cancer and contributes to the resistance of this cancer to therapy. It also regulates the expression of microRNAs in rhabdomyosarcoma and non-small cell lung cancer. The expression of HO-1 may be regulated by hypoxia inducible factors (HIFs) and Nrf2 transcription factor. The expression of HO-1 has not so far been examined in relation to Nrf2, HIF-1α, and potential mediators of angiogenesis in human bladder cancer. We measured the concentration of proinflammatory and proangiogenic cytokines and the expression of cytoprotective and proangiogenic mRNAs and miRNAs in healthy subjects and patients with bladder cancer. HO-1 expression was upregulated together with HIF-1α, HIF-2α, and Nrf2 in bladder cancer in comparison to healthy tissue. VEGF was elevated both at mRNA and protein level in the tumor and in sera, respectively. Additionally, IL-6 and IL-8 were increased in sera of patients affected with urothelial bladder cancer. Moreover, miR-155 was downregulated whereas miR-200c was elevated in cancer biopsies in comparison to healthy tissue. The results indicate that the increased expression of HO-1 in bladder cancer is paralleled by changes in the expression of other potentially interacting genes, like Nrf2, HIF-1α, HIF-2α, IL-6, IL-8, and VEGF. Further studies are necessary to also elucidate the potential links with miR-155 and miR-200c.
In a recent interesting paper Babaei and Stewart [1] demonstrated that coculture of endothelial cells (ECs) with smooth muscle cells (SMCs) may result in the formation of extensive capillary-like structure. However, the effect was observed only when SMCs were previously transfected with vector containing the endothelial nitric oxide synthase (eNOS) cDNA. Such an in vitro angiogenic-like events were abrogated by l-NAME, a NOS inhibitor. A similar angiogenic response has been observed when SMCs were transfected with plasmids containing VEGF121 cDNA, the effect again being inhibited by l-NAME. Similarly, in a Boyden chamber model the EC migration was potently enhanced in the presence of SMC transfected with eNOS or VEGF121, and was significantly attenuated by l-NAME. Much evidence indicates that NO plays an integral role in VEGF signaling (see Ref. [1]). It has …
Type 2 diabetes mellitus (T2DM) is a metabolic disease caused by insulin resistance that leads to changes in glucose metabolism. Importantly, both insulin resistance and hyperglycemia are present in T2DM patients as a hallmarks of metabolic syndrome. They negatively affect functions of many cells, for example endothelial cells. Endothelial progenitor cells (EPC) is a population of mononuclear cells that expresses endothelial and progenitor markers. EPC are also characterized by ability to form tubes on matrigel, outgrowth into mature endothelial cells, produce proangiogenic factors or take part in the blood vessels formation. Upon injury endothelial progenitor cells are mobilized from bone marrow, home to injured site and take part in vessels formation. It was shown however, that functions of EPC in T2DM patients are impaired. In this review we focused on the T2DM and its detrimental effects on EPC biology. taking also into account the beneficiary role of anti-diabetic drugs. Decreased number and impaired functions of EPC in T2DM patients might lead to increased frequency of cardiovascular incidents and development of micro- or macroangiopathies.
No abstract available.
Seminal demonstration of the possibility of stable genetic modification of mammalian cells performed by Wacław and Elisabeth Szybalski opened the doors for gene therapy, the term coined by Wacław Szybalski already in 1962. In the next 60 years, numerous tools for gene delivery have been developed and applied for clinical research, culminating in the registration of several genetic therapies in Europe and the USA. Some of these strategies, aimed to treat severe combined immunodeficiencies, inherited forms of blindness, spinal muscular atrophy, some cancers, and genetic anemias, are the real hope for patients suffering from previously incurable diseases or the ones whose treatment was not effective. On the approaching 60th anniversary of gene therapy, combined with the 100th anniversary of the birth of Professor Wacław Szybalski (September 9th, 1921), who passed away on December 16, 2020, here I present the summary of the most important aspects of clinical applications of genetic therapies.